Search

Your search keyword '"Akdis, C"' showing total 609 results

Search Constraints

Start Over You searched for: Author "Akdis, C" Remove constraint Author: "Akdis, C" Language english Remove constraint Language: english
609 results on '"Akdis, C"'

Search Results

1. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

5. The ARIA-MeDALL hypothesis

7. Implementation of the web-based calculator estimating odds ratio of severe COVID-19 for unvaccinated individuals in a country with high coronavirus-related death toll

8. Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

9. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

10. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products

11. Detection of gut and mucosal peptides through TOMAHAQ in healthy individuals.

15. Non‐allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology

16. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

17. Allergen immunotherapy for insect venom allergy: a systematic review and meta‐analysis

20. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis.

23. Global Allergy Forum and 3rd Davos Declaration 2015: Atopic dermatitis/Eczema: challenges and opportunities toward precision medicine

25. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

26. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

27. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

28. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

29. Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

30. Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis

33. Cabbage and fermented vegetables:from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

34. Food allergy across the globe

38. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology

40. Global Allergy Forum and Second Davos Declaration 2013 Allergy: Barriers to cure – challenges and actions to be taken

41. EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy

44. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases: Review

45. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

46. Efficacy and safety of treatment with dupilumab for severe asthma : A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma

47. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

48. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

49. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B<

50. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Catalog

Books, media, physical & digital resources